MedTrace Logo

Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy

NCT02137863 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-05-14

No results posted yet for this study

Summary

The aim of this study was to evaluate the effects of dexmedetomidine on renal function, hormonal and hemodynamic parameters in contrast media induced diabetic patients.

Conditions

  • Radiographic Contrast Agent Nephropathy

Interventions

DRUG

Dexmedetomidine

Intravenously 1μg/kg/10min administered just before the procedure. 1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography.

DRUG

0.9 % NaCl

During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.

DRUG

0.9 % NaCl

100 ml/10min infusion just before the angiography 1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure

Sponsors & Collaborators

  • TC Erciyes University

    lead OTHER

Principal Investigators

  • Aynur Akın, Prof · TC Erciyes University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-06-30
Completion
2012-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02137863 on ClinicalTrials.gov